Genmab A (GMAB) Cash from Investing Activities (2023 - 2026)

Genmab A has reported Cash from Investing Activities for 4 years, with the latest figure at -$9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 79.07% year-over-year to -$9.0 million; the trailing twelve-month figure through Mar 2026 stood at -$123.0 million (up 95.83% YoY), and the FY2025 full-year result was -$5.6 billion, down 289.98% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$9.0 million, up from -$54.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $21.0 million in Q3 2024, with the low at -$1.5 billion in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$380.4 million across 4 years, with a median of -$54.0 million in 2025.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities tumbled 682.16% — and 2025, when it jumped 98.85%.
• Genmab A's Cash from Investing Activities stood at -$185.0 million in 2023, then plunged by 682.16% to -$1.4 billion in 2024, then surged by 96.27% to -$54.0 million in 2025, then surged by 83.33% to -$9.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$9.0 million (Q1 2026), -$54.0 million (Q3 2025), and -$17.0 million (Q2 2025), per Business Quant data.